Bluejay Diagnostics

Bluejay Diagnostics DSCR

The Debt Service Coverage Ratio (DSCR) of Bluejay Diagnostics (BJDX) as of Nov 5, 2026 is -50.36. In the previous year, Debt Service Coverage Ratio (DSCR) was -35.18 — a change of 43.12% (lower).

DSCR

-50.36

YoY

43.12%

Last updated:

Debt Service Coverage Ratio (DSCR) of Bluejay Diagnostics is 2025 -50.36 . Debt Service Coverage Ratio (DSCR) of Bluejay Diagnostics was 2024 -35.18 . It decreases by 43.12% lower compared to the previous year.

The Bluejay Diagnostics DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2019
-1.58 USD
Jan 1, 2020
-0.48 USD
Jan 1, 2022
-15.72 USD
Jan 1, 2023
-23.55 USD
Jan 1, 2024
-35.18 USD
Jan 1, 2025
-50.36 USD
The Bluejay Diagnostics DSCR history
YEARDSCRYoY
-50.36+43.12%
-35.18+49.38%
-23.55+49.88%
-15.72+3,161.93%
-0.48-69.52%
-1.58—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bluejay Diagnostics Stock analysis

What does Bluejay Diagnostics do? Bluejay Diagnostics Inc generates revenue through its Symphony System, a near-patient testing platform for disease triage and monitoring. The company's first product, the Symphony IL-6 test, provides rapid sepsis diagnostics with results in about 20 minutes, targeting healthcare providers in acute care settings. The Symphony platform processes whole blood to measure key biomarkers, leveraging non-contact centrifugal force for biomarker isolation and immunoassay preparation. This solution addresses the in vitro diagnostics market segment focused on sepsis, cardio-metabolic diseases, and cancer diagnostics. The Symphony System and its initial IL-6 test are designed for medical professionals seeking faster diagnostic decisions in critical care scenarios. Bluejay Diagnostics targets hospitals and clinics requiring rapid biomarker measurements for patient triage and treatment adjustments. The company's focus on near-patient testing differentiates its offerings within the in vitro diagnostics industry, emphasizing speed and accuracy for time-sensitive conditions. Bluejay Diagnostics Inc operates within the health care equipment and supplies sector, with its Symphony platform positioned to serve the global in vitro diagnostics devices market. The company's initial product, the Symphony IL-6 test for sepsis triage, represents a targeted solution for acute medical conditions requiring immediate diagnostic insights. The Symphony analyzer's ability to process whole blood for biomarker measurement supports its application in multiple disease areas including sepsis and cardio-metabolic conditions. Bluejay Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bluejay Diagnostics stock

Debt Service Coverage Ratio (DSCR) of Bluejay Diagnostics is -50.36 in 2025.

Debt Service Coverage Ratio (DSCR) of Bluejay Diagnostics changed from -35.18 to -50.36, representing a 43.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) Bluejay Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s Bluejay Diagnostics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bluejay Diagnostics

All Key Metrics — Bluejay Diagnostics